Psilocybin for Bipolar II Depression

We are conducting a clinical trial to evaluate the safety and therapeutic potential of psilocybin (the active compound in “magic mushrooms”) for individuals diagnosed with bipolar II disorder who are experiencing suicidal thoughts. Participants will receive up to two psilocybin sessions combined with psychotherapy from a licensed therapist over a 16-week period. This research aims to explore psilocybin as a novel treatment option for a population often excluded from psychedelic studies. Eligible participants must be 18–70 years old, fluent in English, and able to attend sessions at our Houston site.